Joseph P. Schlessinger
Founder at Opna Bio SA
Profile
Joseph P.
Schlessinger is the founder of Sugen, Inc. (founded in 1991), Plexxikon, Inc. (founded in 2001), Kolltan Pharmaceuticals, Inc. (founded in 2007), and Inozyme Pharma, Inc. (founded in 2015).
He held the title of Chairman at Plexxikon, Inc. from 2009 to 2010 and Chairman at Inozyme Pharma, Inc. from 2015 to 2020.
Dr. Schlessinger is also the founder of Opna Bio SA. Dr. Schlessinger's current job(s) include Chairman-Pharmacology Department at Yale School of Medicine since 2001, Director-Cancer Biology Institute at Yale University, Member of the Russian Academy of Sciences, Member of the National Academy of Sciences, Member of the National Academy of Medicine (United States), Chief Scientist at Yale Cancer Center, and Member of the European Molecular Biology Organization.
Dr. Schlessinger's former job(s) include Director-Skirball Institute at New York University from 1998 to 2001, Director at StemRad Ltd., and Professor at Weizmann Institute of Science from 1980 to 1991.
Dr. Schlessinger's education history includes undergraduate and graduate degrees from The Hebrew University of Jerusalem and a doctorate degree from Weizmann Institute of Science.
Joseph P. Schlessinger active positions
Companies | Position | Start |
---|---|---|
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT. | Chief Tech/Sci/R&D Officer | - |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | Corporate Officer/Principal | - |
European Molecular Biology Organization | Corporate Officer/Principal | - |
Russian Academy of Sciences | Corporate Officer/Principal | - |
Yale School of Medicine | Corporate Officer/Principal | 2001-11-30 |
Yale University | Corporate Officer/Principal | - |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Founder | - |
Former positions of Joseph P. Schlessinger
Companies | Position | End |
---|---|---|
INOZYME PHARMA, INC. | Founder | 2020-04-30 |
░░░ ░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░ | ░░░░░░░ | - |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Joseph P. Schlessinger
The Hebrew University of Jerusalem | Graduate Degree |
Weizmann Institute of Science | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
INOZYME PHARMA, INC. | Health Technology |
Private companies | 9 |
---|---|
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Commercial Services |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Commercial Services |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | Commercial Services |
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT. | Health Services |
European Molecular Biology Organization | |
StemRad Ltd.
StemRad Ltd. SemiconductorsElectronic Technology StemRad Ltd. develops protective devices against the damages of nuclear radiation. Its technology reduces the nuclear threat by protecting blood-forming stem cells from the effects of lethal gamma radiation. The firm's is developing Personal Protective Equipment (PPE) to protect against the deadly effects of radiation sickness. The company was founded by Oren Milstein and Daniel Levitt in November 2009 and is headquartered in Tel Aviv, Israel. | Electronic Technology |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Health Technology |
- Stock Market
- Insiders
- Joseph P. Schlessinger